ORPHELIA Pharma will participate to the 4th Annual Meeting of the European Society for Paediatric Oncology (SIOPe 2023) to be held May 8-12, 2023 in Valencia, Spain. SIOPe aims to bring together the diverse stakeholders in a unique interactive format to discuss the current priorities and needs in the field of childhood cancers (https://siopeurope.eu/).
We are pleased to announce that Jeremy Bastid, Chief Development Officer, and Hugues Bienaymé, General Manager and Chief Scientific Officer at ORPHELIA Pharma, will attend SIOP Europe 2023. We will be present at booth #10 located near the entrance doors to Auditorium 1. Our booth will showcase the scientific data of our paediatric temozolomide oral suspension (KIMOZO).
If you would like to meet Jeremy or Hugues, please contact them at: email@example.com or firstname.lastname@example.org
KIMOZO 40 mg/ml is a ready-to-use and taste-masked oral suspension of temozolomide. KIMOZO is being developed by ORPHELIA Pharma for the treatment of relapsed or refractory neuroblastoma in pediatric patients aged 12 months and above. KIMOZO is not an approved medicinal product and is made available in certain European countries only via a named patient access program by ORPHELIA Pharma or Tanner Pharma (www.tannerpharma.com).